RCS - Oxford Cannabinoid - Investor Presentation and Q&A – Programmes update

Oxford Cannabinoid Technologies HoldingsAnnouncement

12/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230712:nRSL7136Fa&default-theme=true

RNS Number : 7136F  Oxford Cannabinoid Tech.Holdings  12 July 2023

 

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

 

Investor Presentation and Q&A - Programmes update

 

OCTP will host a live presentation and Q&A via the Investor Meet Company
platform at 16.00 BST on Wednesday 19 July 2023, open to all existing and
potential shareholders.

Recently appointed Chief Medical Officer, Dr Tim Corn and Chief Scientific
Officer, Dr Valentino Parravicini, will discuss developments across the
Company's portfolio.

Investors can sign up to Investor Meet Company for free and add to meet Oxford
Cannabinoid Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
(https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor)

 

Investors who already follow OCTP on the Investor Meet Company platform will
automatically receive an invitation to the event.

 

The Directors of the Company accept responsibility for the content of this
announcement.

 

  Enquiries:

Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Clarissa Sowemimo-Coker (CEO)                 clarissa@oxcantech.com

 Axis Capital Markets Limited

 Richard Hutchison                             +44 (0)20 3026 0320

 Walbrook PR Limited

 Paul Vann                                     +44 (0)20 7933 8780

 Nick Rome                                     +44 (0)7768 807631

 Joe Walker                                    oxcantech@walbrookpr.com

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd (together the "Group"), a
pharmaceutical Group developing prescription cannabinoid medicines targeting
the U$ multi-billion global pain market.

 

OCTP currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN")), with the Phase I clinical trial, aimed at
demonstrating safety and tolerability. Trial results are expected in Q3
2023.
(https://www.londonstockexchange.com/news-article/OCTP/updates-on-lead-programme-1-and-programme-2/15391762)
The global market for CIPN alone is currently valued at US$1.61bn and is
forecast to reach US$2.37bn by the year 2027.

 

OCTP's drug development pipeline comprises both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive license agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen patent
families and associated research data.

 

OCTP has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCTP's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMZGMNGMRGFZZ